Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci
Open Access
- 1 June 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (11) , 4097-4106
- https://doi.org/10.1158/1078-0432.ccr-04-1832
Abstract
Purpose: Our study was designed to evaluate promoter CpG island hypermethylation in the diagnosis and prognosis of prostate cancer.Keywords
This publication has 45 references indexed in Scilit:
- CpG Hypermethylation of MDR1 Gene Contributes to the Pathogenesis and Progression of Human Prostate CancerCancer Research, 2004
- Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate AdenocarcinomaClinical Cancer Research, 2004
- The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complexNature Cell Biology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- P504S Immunostaining Boosts Diagnostic Resolution of “Suspicious” Foci in Prostatic Needle Biopsy SpecimensAmerican Journal of Clinical Pathology, 2004
- Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinomaThe Prostate, 2003
- Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinomaOncogene, 2003
- Pathological and molecular aspects of prostate cancerThe Lancet, 2003
- Methylation-specific PCR (MSP) for detection of tumour DNA in the blood plasma and serum of patients with prostate cancerProstate Cancer and Prostatic Diseases, 2000
- Mutations of theAPC adenomatous polyposis coli) geneHuman Mutation, 1993